Pathophysiology of the antiphospholipid antibody syndrome

Abstract

Antiphospholipid antibodies (aPL) are associated with the recurrent pregnancy loss and thrombosis that characterizes the antiphospholipid antibody syndrome (APS). Although the ontogeny of these pathogenic antibodies has not been fully elucidated, there is evidence that indicates the involvement of both genetic and environmental factors. The ability of aPL to induce a procoagulant phenotype in APS patients plays a central role in the development of arterial and venous thrombotic manifestations typical of the disease. Inflammation serves as a necessary link between this procoagulant phenotype and actual thrombus development and is an important mediator of the placental injury seen in APS patients with obstetric complications. Recent evidence has indicated a role for abnormal cellular proliferation and differentiation in the pathophysiology of APS, especially in those patients with pregnancy morbidity and other more atypical manifestations that have no identifiable thrombotic cause. The interplay of genetic and environmental factors responsible for aPL development and the mechanisms by which these antibodies produce disease in APS patients is the focus of this review.

Introduction

Antiphospholipid antibody syndrome (APS) is an autoimmune multisystemic disorder characterized clinically by recurrent thrombosis and pregnancy morbidity and serologically by the presence of antiphospholipid antibodies (aPL) including anticardiolipin (aCL) and anti-β₂ glycoprotein I (Anti-β₂GPI) antibodies and lupus anticoagulant (LA) [1–3]. It is now widely accepted that aPL are a heterogenous group of antibodies (Abs) that react with a myriad of phospholipids (PLs), PL-protein complexes and PL-binding proteins. The main antigenic target of these antibodies is recognized to be β₂GPI, which along with prothrombin accounts for more than 90% of the antibody-binding activity in APS patients. Other potentially significant antigenic targets include tissue plasminogen activator (tPA), phosphatidylserine (PS), plasmin, annexin 2, activated protein C (APC), thrombin, antithrombin III (AT-III) and annexin V [4–10].

APS was first described in a subset of patients with systemic lupus erythematosus (SLE) and related connective tissue diseases (CTD) that had abnormal LA tests, subsequently being classified as ‘secondary’ APS (SAPS) in the presence of these conditions and ‘primary’ (PAPS) in their absence [11]. In the general population, PAPS is the most common cause of acquired thrombophilia and is a recognized risk factor for the development of deep vein thrombosis (DVT) with or without pulmonary embolism, new strokes in individuals below the age of 50 and recurrent fetal loss [12]. The prevalence of DVT occurrence in the general population is estimated at 2–5%, 15–20% associated with PAPS, suggesting that the prevalence of venous thrombosis associated with PAPS may be as high as 0.3–1% of the general population [12]. APL Abs are present in 30–40% of SLE patients and up to a third of these patients (10–15% SLE patients) have clinical manifestations of APS, especially venous or arterial thromboses [13, 14]. The APS-related thrombotic events range in severity from the relatively benign superficial thrombophlebitis to myocardial infarction, stroke, and catastrophic APS (CAPS) [15]. SAPS also accounts for a significant proportion of recurrent pregnancy loss in SLE patients, indeed, aPL are now regarded as the most frequent acquired risk for a treatable cause of recurrent pregnancy loss and for pregnancy complications (early and severe pre-eclampsia) [13, 16–18].

Apart from the well-recognized arterial and venous thrombotic events typical of APS, these patients can also present with a variety of ‘non-criteria’ manifestations which include thrombocytopenia, nephropathy, livedo reticularis, cardiac valve disease, skin ulcers, diffuse pulmonary hemorrhage and neurological manifestations such as chorea, epilepsy, cognitive dysfunction and transverse myelopathy [19–21]. These manifestations often develop during, and do not improve with, heparin or warfarin anticoagulation therapy highlighting the concept that these manifestations more than likely do not result from the same biological abnormalities that cause arterial and venous thromboembolism in APS patients [19].

The pathophysiology of this disease has its basis in the action of the myriad autoantibodies found in APS patients on their numerous antigenic targets [22]. The origin of these pathogenic autoantibodies still remains a mystery but is likely to be due to the complex interaction of multiple environmental factors in individuals with genetic markers that increase susceptibility to the disease [23, 24]. Perhaps the most studied aspect of the disease is the increased propensity for thrombus formation and this procoagulant phenotype in APS occurs as a result of the synergy of many contributory elements. These include aPL-mediated activation of platelets, monocytes, and endothelial cells and aPL-induced perturbation of natural anticoagulant and fibrinolytic systems [8, 25–28]. Non-thrombotic mechanisms also play a major role in APS and their contribution to the development of obstetric and other more atypical manifestations of the disease has recently been the focus of much research [29, 30]. Abnormal cellular proliferation and differentiation impacting on cell function has been shown to be an important factor in aPL-induced pregnancy morbidity and this is also likely to be one of the main mechanisms involved in the development of those APS disease manifestations for which a thrombotic basis is not clearly identifiable [19, 30–32]. Inflammation is a central pathogenic factor in APS; it serves as a necessary link between the procoagulant phenotype seen in this disease and actual thrombus development and is an essential mediator of placental injury typical of aPL-induced obstetric complications [33, 34]. The proposed genetic and environmental factors contributing to the development of aPL and the mechanisms by which these autoantibodies produce the myriad disease manifestations seen in APS patients is the focus of this review.

Genes and the environment in APS

Various animal models and family and population studies have been used to highlight HLA associations with the disease and the occurrence of aPL in patients. That is to say that Major Histocompatibility Complex (MHC) genes may influence not only autoantibody production but also disease expression itself [35]. Another important consideration is the occurrence of prothrombotic genetic markers that may modify disease expression in APS patients especially when associated with acquired factors such as aPL [36]. These pathogenic aPL are thought to be produced by exposure to certain viral or bacterial products with sequence similarity to host antigens inducing a break in tolerance [37]. As stated previously, aPL represent a heterogenous group of antibodies with many different antigenic targets and the clinical experience is that not all aPL are pathogenic; making it likely that only a limited number of aPL induced by certain viral or bacterial products are important in disease [37, 38]. The roles that genetic and environmental factors play in APS development are summarized in Table 1.

Table 1.

Evidence for proposed mechanisms of genetic and environmental involvement in APS development

Experimental model		Implications/findings
Genetic	Animal studies	• Evidence for antigen driven stimulation for pathogenic aPL production
		• Complementary gene action of 2 independently segregating major dominant alleles produce disease characteristic
		• Role for modifying alleles (e.g. Yaa)
		• Role for hormones in modifying genetic susceptibility
	Human family HLA Studies	• Most consistent associations: HLA-DR4 and DRw53
		• Others: DR7, DQw3, DQw7, A30, Cw3, B60
	Human population HLA studies	• Most consistent associations: HLA-DR4, DR7, DRw53, DQB1*0302
		• Others: DRB1*04, DQB1*0301/4, DQB1*0604/5/6/7/8/9, DQA1*0102, DQA1*0301/2
		• DRB1*09 in Japanese patients
		• C4A/C4B null alleles in African American patients
	Human non-HLA studies	• Several non-HLA genes associated with increased thrombosis [G20210 A, AT-III, F5G1691 A, β2GPI val247leu polymorphism, F13A1, GP1a/IIa polymorphisms]
Environmental	Infectious agents	• Molecular mimicry [e.g. CMV, AdV,H. influenzae, N. gonorrhoae, C. tetani]
		• Selective destruction/activation of unique lymphocyte subsets
		• Cytokine release
		• Cryptic antigen exposure (necrosis/apoptosis)
	Drugs/vaccination	• Neoantigen formation
		• Altered antigen processing and presentation
	Malignancies	• Neoantigen formation (tumor, immunomodulatory therapy)

AdV adenovirus, AT-III antithrombin III, β₂GPI val247leu beta-2 glycoprotein I valine 247 polymorphism, CMV cytomegalovirus, F13A1 factor XIII val 34 polymorphism, F5G1691 A factor V Leiden mutation, G20210 A prothrombin mutation, GP Ia/IIa glycoprotein Ia/IIa, HLA human leukocyte antigen, Yaa Y-linked autoimmune accelerator

Animal genetic studies in APS

There are relatively few animal studies that have assessed the genetic basis for the development of APS. The spontaneous production of IgG aCL antibodies, which exhibit co-factor (β₂GPI) dependent binding to cardiolipin, has been detected in NZW × BXSB F1 (W/B F1) male mice [39]. W/B F1 mice are SLE-prone mice, which develop several autoantibodies, circulating immune complexes, and nephritis in addition to a high incidence of degenerative coronary vascular disease with myocardial infarction and thrombocytopenia and thus represent a model of lupus associated APS [39–41]. Interestingly, analysis of the genes utilized in the production of pathogenic aCL in these mice showed preferential usage of certain V_H and V_κ genes, whereas other non-pathogenic aCL utilize random V gene combinations [42]. This possibly indicates that pathogenic aCL production in these mice is antigen-driven rather than germ line encoded.

In 1998, Ida et al. analyzed APS disease features in BXSB and NZW mice and their progeny [43]. Although male BXSB parental mice showed similar disease features to their male NZW × BXSB F1 progeny, these features were of decreased frequency and intensity and disease was not apparent in female parental NZW or female NZW × BXSB F1 progeny. These findings suggest that genes from the BXSB strain determines, while NZW genes serve to upregulate or modify, APS disease characteristics in their progeny and that modifying alleles such as BXSB Y-linked autoimmune accelerator gene (Y aa) may also play a role [43–45]. In the same study, genome-wide analysis using microsatellite markers was used to map BXSB alleles affecting development of aCL, anti-platelet antibodies, thrombocytopenia, and myocardial infarction in NZW ×  (NZW × BXSB) F1 backcross male progeny [43]. This analysis showed that the generation of each disease character was controlled by two independently segregating major dominant alleles producing full expression as a complementary gene action. Although there was complete genetic concordance between anti-platelet Abs and thrombocytopenia, other disease characteristics were independently controlled by different combinations of two dominant alleles suggesting that no single genetic factor can explain the pathogenesis of APS [43].

The presence of IgG aCL antibodies has also been demonstrated in other lupus-prone mice including the MRL/MP/lpr/lpr (MRL/lpr) and MRL/+/+ mice [46]. Similar to aCL produced in W/B F1 mice, those produced in MRL/lpr mice show non-random V_H and V_κ gene usage and also evidence of somatic mutation indicating a role for antigen-driven affinity maturation [47]. aCL are also produced in normal C57BL/6 J mice with estrogen treatment increasing the incidence and levels of these antibodies, underscoring the role that environmental factors such as hormones may play in modifying genetic susceptibility in APS patients [48]. It is important to note however that aCL produced in these estrogen treated C57BL/6 J mice and those in MRL/lpr mice are not β₂GPI dependent but rather show decreased binding to cardiolipin in the presence of human β₂GPI [49]. Interestingly, NZW × NZB F1 mice, another classic murine model of SLE, fail to produce aCL Abs despite the production of other autoantibodies such as anti-dsDNA [46].

Human family and population studies: HLA and non-HLA associations

Multiple HLA-DR and DQ associations with the occurrence of aPL antibodies have been described but small patient sample sizes and difficulties regarding obtaining appropriately ethnically matched control populations make interpretation problematic [35, 36]. A familial clustering of individuals with persistently false positive tests for syphilis in whom overt autoimmune disease developed years later was perhaps the first indication of familial APS [50]. Since 1980, several studies have described families with high incidences of primary APS associated with LA, aCL and other autoantibodies [51–53]. The increased incidence of aCL antibodies in first-degree relatives of patients with primary or secondary APS with SLE has also been demonstrated [54, 55]. A 1998 study which assessed seven families with a high incidence of primary APS, 30 of 101 family members meeting diagnostic criteria, suggested either a dominant or co-dominant model for inheritance of the disease by segregation analysis but failed to find linkage to HLA and other candidate genes including β₂GPI and Fas [56]. Other family studies however have reported several HLA associations. The paternal haplotype A30; Cw3; B60; DR4; DRw53; DQw3 has been shown to be associated with aCL in an English Canadian family; both in asymptomatic individuals and those with APS secondary to SLE and autoimmune thyroid disease [57]. The occurrence of LA in families with haplotypes containing either DR4 or DR7 has also been demonstrated [58, 59]. In a family study in which all members had SLE and presented with various APS manifestations, a mother and her twins shared a haplotype that included DR4, DRw53 and DQw7 [60].

Non-familial population studies also highlight several HLA associations of APS. A 1991 study of 20 patients with SLE and LA demonstrated an association with HLA-DQw7 (HLA-DQB1*0301) linked to HLA-DR4 and/or -DR5 [61]. In 13 English patients with primary APS, DR4 and DRw53 were found with increased frequency [62]. Other HLA loci associated with primary APS include DRB1*04, DR7, DQB1*0301/4, DQB1*0604/5/6/7/9, DQA1*0102, and DQA1*0301/2 [63–65]. In a large Italian study in SLE patients, aCL were positively associated with HLA-DRB1*04, -DRB1*07, -DQA1*0201,-DQA1*0301,-DQB1*0302,-DRB3*0301 and anti-β₂GPI positively associated with DQB1*0302 [66]. The association of aCL with DRB1*09 has been reported in Japanese patients with APS secondary to SLE [67] Anti-β₂GPI in Caucasian and Mexican Americans is strongly associated with HLA-DR4 haplotypes, especially those carrying HLA-DQ8 (DQB1*0302) while in African American and white British patients with primary APS, anti-β2GPI is strongly associated with the HLA-DRB1*1302;DQB1*0604/0605 haplotype [63, 68]. The association of C4A or C4B null alleles with the presence of aCL has been reported in black American populations, however, patients in the Hopkins Lupus Cohort who were homozygous for C4A deficiency had a lower frequency of aCL and LA than patients without this deficiency [69–71].

Other genes outside the MHC region also contribute to both autoantibody production and disease expression in APS. A polymorphism in domain 5 of β₂GPI, valine instead of leucine at position 247, is found more frequently in patients with APS than matched controls and is associated with anti-β₂GPI production in these patients [72–74]. One study found an increased frequency of this polymorphism in patients with arterial thrombosis than those without [75]. There are other prothrombotic genetic factors that can modify disease expression in APS patients. Those genetic factors clearly related to thrombophilia that have been seen in APS patients include factor V Leiden and prothrombin mutations and antithrombin III, protein C and protein S deficiencies [75]. The gain of function factor V Leiden G1691A (FVL) mutation is highly prevalent in Caucasian populations with population frequencies ranging from 1 to 15% [76, 77]. Several reports have demonstrated an increased incidence of thrombosis in APS patients with FVL mutation when compared to those without but the mutation seems to have a more moderate effect on the development of thrombosis in APS than in the general population [78–80]. The G20210A prothrombin mutation (F2 G20210A) is associated with venous thromboembolism in the general population but there have been conflicting reports of the increased risk of thrombosis related to this gene mutation in APS patients. Initial reports indicated no increased risk but some of the subsequent studies have demonstrated the association between the mutation and thrombosis in APS patients, the first case being described in a young female with SLE-associated APS homozygous for the G20210A mutation [81–84]. Protein C, S and antithrombin III deficiencies are uncommon diseases making it difficult for an accurate assessment to be made of the relative contributions of these mutations and aPL in thrombus generation in APS. However there have been reports of increased thrombosis rates in APS patients with protein C and protein S deficiency [85, 86]. Other polymorphisms that potentially impact the risk of thrombosis in APS patients affect platelet glycoproteins GP Ia/IIa and GP IIb/IIIa, platelet Fcγ receptor IIa, tissue factor pathway inhibitor, thermolabile variant of methylenetetrahydrofolate reductase, type-I plasminogen activator inhibitor, tumor necrosis factor α, thrombomodulin, annexin A5, p-selectin, p-selectin glycoprotein ligand-1, toll-like receptor 4, factor XIII and CD40 [87–97].

Origin of aPL: environmental factors

The processes underlying the production of aPL in APS patients remain undetermined. When these antibodies were first described, aPL were defined as antibodies reacting to cardiolipin, however, it is now well accepted that these antibodies recognize various PL and protein antigenic complexes [4–7]. Indeed, as stated previously, the main antigenic target for these antibodies is β₂GPI, an abundant serum protein that is a necessary co-factor for aPL binding to phospholipid. In fact, efforts to induce high-titer production of pathogenic aPL in animal models succeeded only after immunization with heterologous β₂GPI rather than pure phospholipids [4, 98]. This led researchers to believe that perhaps in vivo binding of foreign PL-binding proteins resembling β₂GPI to self-phospholipids in APS patients may lead to the formation of immunogenic complexes against which aPL is produced. A synthesized 15 amino acid peptide, GDKV, which spanned an area of the fifth domain of β₂GPI known to be a major PL-binding site of the molecule, was able to induce pathogenic aPL and anti-β₂GPI production in immunized mice [99]. A monoclonal Ab with aPL and anti-β₂GPI activity generated from these GDKV-immunized mice was shown to be pathogenic using in vivo models for thrombus enhancement and microcirculation [100]. Similar results were subsequently obtained using peptides from microorganisms with functional and sequence similarity to that of the PL-binding site of β₂GPI [101]. The peptides TIFI and VITT from cytomegalovirus (CMV), TADL from adenovirus (AdV) and SGDF from Bacillus subtilis all had greater degrees of PL-binding compared to GDKV and induced high-titer aPL and anti-β₂GPI production in mice. Subsequent in vivo and in vitro experiments confirmed the pathogenicity of antibodies induced in TIFI-immunized mice [101–103].

Further supporting evidence for molecular mimicry as a possible mechanism for APS development was provided by a study evaluating the APS-related pathogenic potential of microorganisms carrying sequences related to a hexapeptide, TLRVYK, known to be specifically recognized by a pathogenic monoclonal anti-β₂GPI Ab [104]. Following immunization with Haemophilus influenzae, Neisseria gonorrhoeae or tetanus toxoid; high titers of antibodies with anti-peptide (TLRVYK) and anti-β₂GPI activity were observed in BALB/c mice. These affinity-purified antibodies were then infused into naive mice at day 0 of pregnancy. At day 15, these mice had significant thrombocytopenia, prolonged activated partial thromboplastin times (aPTT) and increased frequency of fetal loss compared to controls.

Infections are thought perhaps to be the most prominent environmental trigger for aPL production and APS development. Syphilis was the first infectious disease recognized to be linked to aPL production and these infectious type aPL were initially thought to be non-pathogenic [105–107]. However, several subsequent reports have shown that many infections not only trigger aPL production but are associated with the development of APS manifestations as well [108]. This is perhaps best exemplified by catastrophic APS, a rare presentation of APS characterized by multiple small vessel occlusions affecting multiple organ systems with a high mortality rate, which is strongly linked to preceding infections and/or trauma [15]. CMV, parvovirus B19, Human immunodeficiency virus (HIV), Hepatitis B and C viruses, Human T cell lymphoma/leukemia virus (HTLV) and Varicella Zoster Virus (VZV) are just a few of the infectious agents that have reported associations with aPL production and APS manifestations [109]. In addition to molecular mimicry, infectious agents can potentially induce autoimmune responses by selectively activating or destroying unique lymphocyte subsets, directing cytokine/chemokine release or exposing cryptic autoantigens during cell necrosis and/or apoptosis [110–112]. Other potential environmental triggers of APS development include vaccination, drug therapy and certain malignancies. However, to date there is no conclusive evidence linking vaccination to the development of APS [113, 114]. The ability of drugs to bind and perhaps alter the processing and presentation of self-antigens such that cryptic antigens are presented makes the development of an autoimmune response possible [115]. Indeed, agents such as chlorpromazine, amoxicillin, phenytoin, chlorothiazide, propranolol, oral contraceptives, quinine, alpha-interferon and infliximab have been associated with the presence of aPL but data regarding the prevalence of drug-induced aPL in APS is still lacking [105, 116]. The presence of aPL has been reported in patients with both solid and hematological malignancies and the significance of this finding lies in the increased risk for thrombosis and the potential for precipitating CAPS in these patients. The mechanisms leading to aPL production remain unclarified but may result from an immune response directed against tumor antigens or perhaps against neoantigens formed due to immunomodulatory drug therapy such as interferon-α (IFNα) [117].

The relative degree to which genetic and environmental factors influence susceptibility to APS development is still uncertain. It is likely that there is a complex interplay of multiple environmental factors in a genetically susceptible patient to produce the varied autoantibodies and myriad clinical manifestations typical of this disease. Improved understanding of the relative contributions of these many factors would certainly aid in prevention and management of these patients.

Thrombogenic mechanisms in APS pathophysiology

There is overwhelming evidence of the thrombogenic capacity of aPL provided by both in vitro studies and in vivo animal models [118]. The main targets of aPL action, β₂GPI and prothrombin (PT), are proteins that interact with many factors involved in hemostasis making the central role that aPL-mediated thrombosis plays in APS unsurprising [4, 5, 119]. Platelet, endothelial cell and monocyte activation occurs in conjunction with disruption of natural anticoagulant and fibrinolytic systems in response to aPL resulting in a procoagulant phenotype in APS patients (Fig. 1) [118]. However, the clinical observation that thrombosis is only occasionally observed despite the persistent presence of aPL suggests that the procoagulant state induced by these antibodies (‘first hit’) only leads to thrombosis in the presence of an inciting factor (‘second hit’) such as inflammatory responses or trauma [120]. The role that inflammatory responses play in thrombus formation in APS is discussed later.

Fig. 1.

Thrombogenic mechanisms of antiphospholipid antibodies (aPL). Y− inhibitory aPL action Y+ aPL-induced activation, Straight green arrow activation, broken red arrow inhibition. AnnA2 annexin A2, APC activated protein C, ApoER2′ apolipoprotein E receptor 2′, AT-III antithrombin III, β-2GPI beta-2 glycoprotein, C5a activated complement component 5, C5aR C5a receptor, Flt-1 tyrosine kinase receptor, GPIb-V-IX glycoprotein Ib-V-IX, GPIIb/IIIa glycoprotein IIb/IIIa, ICAM-1 intercellular adhesion molecule-1, IL interleukin, LPa lipoprotein a, MAC membrane attack complex, NF-κB nuclear factor-kappa B, p38 MAPK p38 mitogen activated protein kinase, PAI-1 plasminogen activator inhibitor-1, PMN polymorphonuclear leukocyte, TF tissue factor, TLR4 toll-like receptor 4, TNFα tumor necrosis factor alpha, tPA tissue plasminogen activator, TXB2 thromboxane-B2, VCAM-1 vascular cellular adhesion molecule – 1, VEGF vascular endothelial growth factor

Cells of the coagulation system

A role for platelet activation in the pathophysiology of APS was initially suggested by the frequent finding of thrombocytopenia in APS patients and APS animal models [121]. Elevated urinary secretion of 11-dehydro-thromboxane B2 (11-dehydro-TXB2), a major platelet derived thromboxane metabolic breakdown product, in APS patients with elevated LA levels indicates this as well [122]. Binding of aPL Abs to platelets is dependent on both the presence of dimeric β₂GPI and the exposure of anionic phospholipids, especially phospatidylserine (PS), on platelets which occurs after stimulation by agonists such as thrombin, collagen, and adenosine diphosphate (ADP) [123, 124]. aPL Abs enhance the expression of GPIIb/IIIa, a major fibrinogen receptor, on platelets and Pierangeli et al. showed that aPL-mediated thrombus formation was significantly reduced in GPIIb/IIIa deficient (β₃-null) mice and mice treated with a monoclonal anti-GPIIb/IIIa antibody [125, 126]. The intracellular mechanisms through which aPL activate platelets was also elucidated by this group. They showed that aPL-induced TXB2 production in platelets through the activation of p38 mitogen activated protein kinase (MAPK) and subsequent phosphorylation of cytosolic phospholipase A2 (cPLA2). Other MAPK pathways in platelets, such as ERK-1 (p44 MAPK) and ERK-2 (p42 MAPK), have a potential role in signaling after initial activation through p38 MAPK [126]. Researchers have demonstrated the role that apolipoprotein E receptor 2′ (ApoER2′) and the GPIbα subunit of the GPIb-V-IX receptor on the platelet membrane play in aPL-mediated platelet activation through the p38 MAPK pathway and subsequent thrombus formation in several studies [124, 127]. Interestingly, these 2 receptors are able to form a complex on the platelet membrane and recently Urbanus et al. reported that anti-β₂GPI/dimeric β₂GPI complex mediated signaling through both these receptors is required for platelet activation [128]. This suggests that perhaps there is a critical role for complex formation of these two receptors in aPL-mediated platelet activation. A recent study has demonstrated a putative role for platelet factor 4 (PF4), a CXC chemokine secreted and bound by platelets, in the stabilization of dimeric β₂GPI and subsequent binding to ant-β₂GPI Abs and exposed phospholipids and receptors on the platelet surface [129].

Like platelet activation, a role for vascular endothelial cell and monocyte activation in aPL-mediated thrombogenesis has been described. Several in vitro studies have shown that endothelial cells express significantly higher amounts of the adhesion molecules vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin [130–132]. Employing in vitro and in vivo experiments utilizing ICAM-1, VCAM-1, E-selectin and P-selectin knockout mice, Pierangeli et al. demonstrated that the ability of human polyclonal and monoclonal aPL to activate endothelium promoting leukocyte adhesion and thrombus formation is mediated by ICAM-1, E-selectin, P-selectin and VCAM-1 [133]. This group and others have also demonstrated the upregulation of tissue factor (TF) expression and microparticle formation with associated increases in interleukin-6 (IL-6) and IL-8 secretion in endothelial cells and monocytes treated with aPL [134–137]. This TF upregulation in monocytes may occur as a result of stimulation of the Flt-1 tyrosine kinase receptor by vascular endothelial growth factor (VEGF); increased plasma levels of VEGF and surface expression of both VEGF and Flt-1 on monocytes being noted in APS patients [138]. The aPL-induced activation and TF upregulation in both endothelial cells and monocytes has been shown to be dependent on p38 MAPK activation and nuclear factor κB (NF-κB) [139, 140]. Many researchers have provided evidence that upregulated TF mRNA and antigen expression and TF pathway activation plays a key role in APS thrombotic manifestations. Indeed, Pierangeli et al. found, in an ongoing clinical trial, that mean serum levels of soluble TF, tumor necrosis factor-α (TNFα) and VEGF were significantly elevated in APS patients compared to controls and treatment with fluvastatin, a statin with efficacy in treating APS, resulted in significant decreases of these pro-inflammatory markers in most APS patients [141].

There is substantial evidence to show that β₂GPI binds to endothelial cells, providing suitable epitopes for aPL binding to endothelial cells. However, the full details regarding the identity of these receptors that bind β₂GPI and the mechanisms by which signaling cascade activation occurs have not been elucidated [142]. Annexin A2 and toll-like receptor 4 (TLR4) have been identified as candidate receptors on both endothelial cells and monocytes and ApoER2′ on endothelial cells as well [139, 143]. Annexin A2 is able to bind anti-β₂GPI/β₂GPI complexes on both endothelial cells and monocytes leading to activation and expression of a procoagulant phenotype [143]. Romay-Penabad et al. have also demonstrated the protective effect of annexin A2 deficiency in mice against the development of aPL-induced thrombosis [144]. However, annexin A2 on the cell surface lacks an intracellular tail meaning that a co-receptor would be required for intracellular signal transduction and subsequent cell activation as a result of anti-β₂GPI/β₂GPI complex binding [143]. Raschi et al. showed that the myeloid differentiation factor 88 (MyD88) signaling cascade, which is important in TLR signaling, is triggered by binding of aPL on human endothelial cells in vitro [139]. A subsequent in vivo study by Pierangeli et al. in lipopolysaccharide (LPS) non-responsive mice (LPS −/−) displaying a single point mutation on the TLR4 gene demonstrated reduced TF expression, endothelial cell activation and thrombosis in response to aPL [97]. These findings indicate that TLR4 may serve as a co-receptor for annexin A2 binding of anti-β₂GPI/β₂GPI complexes and subsequent endothelial cell activation. There is also evidence for annexin A2 and TLR4 acting as co-receptors for these complexes on human monocytes [145]. A very interesting study recently demonstrated that IgGs from APS patients with differing clinical manifestations of the disease vary in their ability to activate NF-κB and p38 MAPK and increase TF production in monocytes and that this was possibly due to differential TLR4 activation [146]. Of note, TLR2 has been shown to play a role in anti-β₂GPI mediated activation of fibroblasts through a MyD88 dependent pathway [147]. Since TLR2 and TLR4 have several shared ligands and TLR2 is also present on endothelial cells, monocytes and platelets, it is possible that TLR2 is involved in aPL-mediated activation of these cells as well [148]. In fact, a recently published study presented evidence for TLR2 being the major TLR involved in aPL-induced endothelial cell activation [149]. Recently, Doring et al. showed that monoclonal aPL and polyclonal IgG from APS patients induced TNFα production in monocytes by activating TLR8, a member of the endogenous group of TLRs [150]. Previous evidence provided by the same group had suggested a role for endogenous stimulation of both TLR7 and TLR8 in the production of pro-inflammatory mediators in APS patients [151]. ApoER2′ is also expressed on endothelial cells and in vitro studies utilizing anti- ApoER2′ antibodies have shown partial inhibition of β₂GPI dependent aPL binding to and subsequent activation of endothelial cells [152]. A recent in vivo study by Romay-Penabad et al. has demonstrated in ApoER2′ deficient (−/−) mice, a significant reduction in thrombus formation and TF production induced by polyclonal IgG aPL, a murine anti-β₂GPI monoclonal Ab (E7) and a constructed β₂GPI dimer compared to wild type controls. A similar effect was noted in wild type mice treated with soluble binding domain I of ApoER2′ (sBD1), an inhibitor of ApoER2′, thus highlighting the importance of this receptor in the pathogenesis of APS [153].

Anticoagulation and fibrinolytic systems

Interference with natural anticoagulant and fibrinolytic systems also plays a role in thrombus formation in APS patients [152, 154]. Activated protein C (APC), in conjunction with its main co-factor protein S, is an important anticoagulant that functions by binding and inactivating the activated forms of coagulation factors V (FVa) and VIII (FVIIIa) [155]. Anti-β₂GPI/β₂GPI complexes potentially affect the assembly and function of APC thus inducing a procoagulant phenotype [156]. Interestingly, anti-PT antibodies in APS patients may also affect APC function [156]. The clinical relevance of these antibodies, as evidenced by association with thrombosis and LA activity, seems to be seen with anti-PT complexed to PS rather than anti-PT itself [157]. Antithrombin III (AT-III) is another natural anticoagulant that performs its function by inactivating the activated forms of factors XII (FXIIa), XI (XIa), X (FXa), IX (FIXa), VII (FVIIa) and thrombin (FIIa), these actions being potentiated by heparin [158]. The inhibition of AT-III activity in vitro by polyclonal IgG and IgM and purified anti-heparan sulfate antibodies from APS patients has been described [159–161]. Annexin A5 is a calcium dependent cationic protein that binds anionic PL, especially PS, with high affinity and functions as a protective anticoagulant shield by competing for sites on PL membranes where coagulation factors normally assemble into active complexes. This protein is found in abundance in placental tissue and is an important natural mediator of anticoagulation at this site [162]. The disruption of this anticoagulant’s function and its possible importance in aPL-mediated pregnancy morbidity is discussed later in this review.

The fibrinolytic system is activated when the proenzyme plasminogen is converted to plasmin which then degrades fibrin, a major component of thrombi. This process is primarily mediated through the action of tissue plasminogen activator (tPA) or urokinase plasminogen activator, the former being more important in coagulation homeostasis. The activity of tPA itself is primarily regulated by the serine protease inhibitor, plasminogen activator inhibitor type I (PAI-1) [154]. Anti-tPA antibodies correlated with reduced tPA plasma levels and the ability to bind and inactivate tPA have been described in APS patients [163]. Elevated PAI-1 levels and decreased tPA release after venous occlusion in APS patients has also been reported [164]. Atrium et al. also reported elevated levels of lipoprotein a (LPa), which shares structural similarity to plasminogen, in the plasma of APS patients. Their experiments suggested that LPa may compete with plasmin or plasminogen for binding to fibrin and others have demonstrated LPa upregulation of PAI-1 expression by human endothelial cells [165]. Some aPL have been reported to bind plasmin thus inhibiting fibrinolysis; one study reporting a frequency of 28% of these antibodies in APS patients [166].

In addition to the role of annexin A2 as a receptor for anti-β₂GPI/β₂GPI complex mediated endothelial cell activation, experimental evidence has shown that cell surface annexin A2 stimulates the activation of plasminogen by tPA [167]. Antibodies that act against annexin A2 and correlate with a history of thrombosis have been shown to be significantly more prevalent in APS patients than in healthy individuals, patients with non-autoimmune thrombosis and SLE patients without thrombosis [168]. IgG anti-annexin A2 Abs have been shown to limit plasmin generation in in vitro experiments on human umbilical vein endothelial cells by 34–83% [9]. Interestingly, β₂GPI has demonstrated the capacity to block PAI-1 activity and also to directly increase plasmin generation by binding to plasminogen [169–171]. These mechanisms of β₂GPI mediated fibrinolysis enhancement have been inhibited by monoclonal anti-β₂GPI and polyclonal IgG from APS patients [172].

Thrombosis in aPL-mediated pregnancy morbidity

Due to the prothrombotic nature of APS, impairment of maternal-fetal blood exchange as a result of thrombus formation in the uteroplacental vasculature was thought to be the main pathogenic mechanism underlying pregnancy morbidity in this condition [173]. Histological examination has supported this hypothesis; placental thrombosis and infarction being demonstrated in APS patients with first and second trimester abortions [174, 175]. IgG fractions from LA positive APS patients are able to induce a procoagulant phenotype with significant increases in thromboxane synthesis in placental explants from normal human pregnancies [176]. As stated previously annexin A5 is thought to be an important anticoagulant during pregnancy acting as a shield on potentially thrombogenic anionic membrane surfaces in the placenta [162]. Rand et al. have reported significantly lower levels of annexin A5 covering the intervillous surfaces of placentas in women with aPL when compared to controls [177]. In vitro studies have also demonstrated displacement of annexin V from trophoblast and endothelial cell monolayers by aPL while murine studies have demonstrated the necessity of this protein in maintaining placental integrity [178, 179]. Anti-annexin A5 Abs have been reported in APS patients at frequencies up to 30% and several studies have demonstrated the association of these Abs with recurrent fetal loss in APS patients [180, 181].

Despite experimental models providing evidence for a role of thrombosis in APS-related pregnancy losses, epidemiological studies fail to demonstrate this consistently. In fact, histological evidence of thrombosis in the uteroplacental circulation cannot be demonstrated in the majority of placentas from APS patients [182]. Other theories have thus been put forward to explain APS-related pregnancy morbidity such as defective trophoblast invasion and decidual transformation in early pregnancy and placental injury as a result of local inflammatory events [183]. It is likely that abnormalities of early trophoblast invasion and defective placentation rather than thrombosis may be the primary pathological mechanism involved in first trimester losses in these patients (Fig. 2) [184].

Fig. 2.

Pathogenic mechanisms leading to obstetric complications in APS. EGF-like GF epidermal growth factor-like growth factor, hCG human chorionic gonadotrophin, MMP matrix metalloproteinases, TF tissue factor, VEGF vascular endothelial growth factor

Non-thrombotic mechanisms in APS pathophysiology

Cellular dysfunction in obstetric APS

There is evidence for a direct effect of aPL on trophoblasts resulting in increased apoptosis and abnormal proliferation, human chorionic gonadotrophin (hCG) release, invasiveness and adhesion molecule expression. There is also evidence for an effect of aPL on maternal spiral artery transformation and the maturation and differentiation of maternal decidual endometrial cells [183]. The direct reactivity of aPL on these cells is supported by the fact that β₂GPI is normally expressed on trophoblast membranes under physiological conditions which also explains the placental tropism of aPL. There is a high level of tissue remodeling during placentation so that trophoblasts, which are able to synthesize β₂GPI, normally express anionic phospholipids on the outer leaflet of the cell membrane allowing β₂GPI binding [185].

Normal placentation involves a dynamic and complex interaction between trophoblast and decidual cells requiring finely regulated cell surface adhesion and signaling molecule expression, activation of matrix metalloproteinases (MMPs), angiogenesis and spiral artery transformation [186]. In vitro studies utilizing murine and human monoclonal aPL and polyclonal IgG Abs from APS patients have demonstrated β₂GPI dependent binding of these Abs to trophoblast monolayers [187, 188]. Bound murine monoclonal anti-PS Abs have been shown to react with syncytiotrophoblast and to prevent intertrophoblast fusion, trophoblast invasiveness and hCG secretion [189, 190]. Comparable results were reported using polyclonal IgG fractions from APS patients and IgM monoclonal anti-β₂GPI Abs [187]. Similarly, anti-β₂GPI mAbs have demonstrated an inhibitory effect on the proliferation of a human choriocarcinoma cell line and on extravillous trophoblast differentiation [189, 191]. In an in vitro model of trophoblast invasion, aPL induced trophoblast expression of particular integrins and cadherins, affecting decidual invasion [192]. Di Simone et al. showed recently that decreased expression of heparan binding epidermal growth factor-like growth factor (EGF-like GF), an important factor in blastocyst implantation, might also play a role in defective placentation [193]. Increased apoptosis has been demonstrated in rat embryos and placental explant cultures incubated with polyclonal IgG from women with SLE/APS and associated pregnancy loss as well as in rat embryos incubated with monoclonal anti-PS Abs [194, 195]. However, human monoclonal IgM anti-β₂GPI Abs failed to induce apoptosis in trophoblast cell monolayers despite affecting Bcl-2 and Bax expression [196].

It has been shown that aPL, particularly anti-β₂GPI, also react with human stromal decidual cells in addition to trophoblasts thus affecting the maternal side of the placenta. Polyclonal and monoclonal β₂GPI dependent aPL can bind stromal decidua cell monolayers and induce a pro-inflammatory phenotype characterized by increased ICAM-1 expression and TNFα secretion [197]. Impaired endometrial differentiation as well as diminished expression of the complement regulatory protein DAF (decay accelerating factor) have been demonstrated in endometrial biopsy samples from APS patients with recurrent pregnancy loss [198]. In a recent study assessing in vitro human endometrial endothelial cell (HEEC) angiogenesis and in vivo angiogenesis in a murine model, aPL were shown to significantly decrease the number and total length of tubule formation, VEGF and MMP production and NF-κB DNA binding activity in HEEC. Newly formed vessels were also reduced in aPL inoculated mice suggesting that inhibition of angiogenesis is a potential mechanism of defective placentation in APS patients [199].

For the most part the candidate cell membrane receptors and the signaling pathways involved in β₂GPI dependent aPL effects on trophoblast and stromal decidual cells remain unknown. Both annexin A2 and TLR4 have been reported to be expressed on trophoblast membranes and a recent study by Mulla et al. has demonstrated that aPL triggers a placental inflammatory response via the TLR4/MyD88 pathway compromising trophoblast survival [200–202]. The same group subsequently showed that anti-β₂GPI Abs limit trophoblast cell migration by down-regulating trophoblast IL-6 secretion and signal transducer and activator of transcription 3 (STAT-3) activation [203]. Inhibitory antibodies to candidate receptors in decidual cells (i.e., TLR4, annexin A2 and ApoER2′) have induced partial inhibition of anti-β₂GPI mediated binding and cellular activation suggesting that perhaps more than one receptor mediates the interaction between β₂GPI and cells of the decidua and trophoblast [197].

Non-thrombotic pathogenic mechanisms in other organ systems

Thrombotic pathogenic mechanisms have failed to explain several other clinical manifestations in APS apart from those related to pregnancy morbidity. Renal involvement in APS, although involving thrombosis in glomeruli and larger vessels, is also associated with non-thrombotic kidney lesions that are associated with an increased risk of end-stage renal disease development. Endothelial cell dysfunction induced by aPL is likely to play a major role [204]. Central nervous system (CNS) involvement in APS, although commonly due to stroke or transient ischemic attack (TIA), is not always associated with a clearly identified ischemic event [205]. Both cognitive dysfunction and magnetic resonance imaging (MRI) white matter hypodensities can occur in aPL positive patients but little is known of the pathogenic mechanisms that lead to the development of these manifestations. An association exists among cognitive dysfunction, livedo reticularis and white matter MRI lesions suggesting a microangiopathic mechanism [206]. In addition to small vessel thrombosis, cognitive dysfunction in APS may be due to aPL binding to CNS cells causing permeabilization and depolarization [207]. Diffuse alveolar hemorrhage (DAH) is an unusual disease presentation in APS. Although some case reports of APS patients with DAH describe lung biopsy specimens with microvascular thrombosis, others revealed pulmonary capillaritis as the main pathogenic finding with no evidence of thrombosis [208, 209]. Furthermore, the fact that appropriately anticoagulated APS patients can present with DAH suggests a vasculitic, non-thrombotic pathogenesis [210]. Several in vivo and in vitro studies have highlighted the contribution of aPL to atherosclerotic plaque formation through endothelial cell and monocyte activation. The formation of atherogenic oxidized low-density lipoprotein (LDL)-β₂GPI complexes and aPL promoting the binding of these complexes to macrophages plays a central role in this process [211, 212].

Inflammation in APS pathology

Inflammatory mediators in APS-related pregnancy morbidity

Several pathogenic changes in maternal immune responses occur during pregnancy in order to protect the developing fetus from attack by the maternal immune system. Key features of this change include the increased prevalence of a Th2 type cytokine profile and an anti-inflammatory environment as dictated by a delicate dynamic equilibrium between pro and anti-inflammatory mediators at different stages of gestation. Acute inflammatory events are generally believed to be responsible for a negative pregnancy outcome and it is therefore reasonable that APS-related pregnancy morbidity may be associated with a pro-inflammatory state in uteroplacental tissue [213]. Experimental models have demonstrated a role for complement, TF, TNFα and CC chemokines in aPL-mediated fetal loss [214, 215].

Initial murine models used to evaluate the role of complement activation in aPL-induced fetal loss had focused on complement components C3 and C5. Passive transfer of large amounts of human IgG-aPL from APS patients with recurrent miscarriage to pregnant naïve mice induced extensive placental damage resulting in increased resorption and fetal growth retardation at day 15 of pregnancy [214]. Placental inflammation in these mice was characterized by recruitment of neutrophils, upregulated TF and TNFa secretion, decidual focal necrosis and apoptosis, loss of fetal membrane elements and complement deposition. Complement receptor 1 related gene/protein y (Crry)-Ig, which is an inhibitor of classical and alternative pathway complement C3 convertases, was shown to reduce the frequency of fetal resorption, prevent growth restriction in surviving fetuses and limit the development of placental lesions [216]. The importance of C3 in aPL-induced pregnancy complications was also confirmed by the resistance of C3 deficient mice to these antibody effects. Interestingly, C4 or factor B deficient mice show similar resistance pointing to the involvement of all complement pathways in aPL-mediated pregnancy morbidity [217]. This indicates perhaps that the classical and/or lectin pathways generate C3, a central component of all the complement pathways, at sites of injury, which then activates a positive feedback loop through the alternative pathway thus amplifying the response.

Additional murine studies have demonstrated the key role that complement component C5 plays in aPL-induced placental injury; aPL-induced pregnancy complications were reduced in C5 or C5a receptor (C5aR) deficient mice and in mice treated with monoclonal anti-C5 Abs or a highly specific peptide antagonist of C5aR (C5aR-AP) [217]. These findings highlight the critical importance of C5a-C5aR interaction in inducing aPL antibody mediated placental injury. C6 deficient mice on the other hand are not protected from aPL-mediated fetal loss indicating that the membrane attack complex (MAC, C5b-9) is unlikely to play an essential role in this process [218]. Interestingly, deciduas from C5 −/− mice treated with aPL had normal morphology with absent neutrophil infiltration and in similar experiments mice depleted of neutrophils did not have pregnancy loss, fetal growth restriction or inflammatory infiltrates [217]. In addition, murine studies utilizing mice treated with monoclonal anti-TF Abs or TF deficient mice were similarly protected from aPL-induced obstetric complications [218]. Redecha et al. showed that a neutrophil oxidative burst associated with TF production was an essential factor in IgG aPL-mediated fetal loss in a murine model and that this pro-inflammatory response could be induced by C5a activation of neutrophils [218]. Studies have also suggested a possible role for C5a activation of monocytes resulting in soluble VEGF receptor-1 (sVEGFR-1) and subsequently diminished VEGF levels in conditions associated with fetal loss [219]. All these findings together suggest a mechanism by which aPL bind trophoblast and induce complement activation, generating C5a and subsequent C5a-C5aR interactions including those on neutrophils and monocytes. C5a induces TF expression and superoxide production in neutrophils causing oxidative damage and possibly sVEGFR-1 secretion in monocytes causing diminished VEGF levels and inadequate placental development and perfusion. This results in placental injury, fetal growth restriction, or resorption. Pro-inflammatory chemokines have also been shown to be important factors in the development of aPL-induced pregnancy complications. Mice deficient in D6, an abundant chemokine receptor in placental tissue that targets inflammatory CC chemokines for destruction, are more susceptible to fetal loss when passively infused with human IgG aPL from women compared to wild type mice [215]. It is important to note that the efficacy of heparin in preventing obstetric complications in women with APS has been shown not to be a function of its ability to inhibit thrombosis, as was once believed, but rather its ability to limit aPL-induced complement activation and subsequent placental inflammation [220].

Conclusive immunohistological evidence of complement activation in abortive material and placentas from women with APS is still lacking. While complement deposition in abortive specimens from APS patients has been reported in some case series, others were unable to demonstrate this pathological finding [221, 222]. Although increased inflammatory infiltrates have been noted in placental biopsies taken from women with APS compared to controls, these inflammatory cells consist predominantly of macrophages, not the polymorphonuclear leukocytes typical of murine models of aPL-induced placental injury [223]. Further analysis of the applicability of murine models to aPL-induced obstetric complications in APS patients is thus required to translate these findings into the development of targeted therapies for these patients. In that line, a prospective multicentre observational study entitled PROMISSE (PRedictors of PRegnancy Outcome: bioMarkers in antiphospholipid antibody Syndrome and SLE - NCT00198068) has been initiated to examine the role of complement as a potential surrogate marker that predicts poor pregnancy outcomes in APS patients. This study is scheduled for completion in 2013 [224].

Role of complement in endothelial cell activation and thrombosis

In addition to its role in aPL-mediated pregnancy morbidity, complement also plays an important role in endothelial cell activation and thrombosis. In murine models of thrombus formation due to aPL action, mice deficient in C3 and C5 were found to be resistant to thrombosis and endothelial cell activation. Monoclonal Abs against C5 reduced thrombus formation and endothelial cell activation in CD1 mice injected intraperitoneally with IgG aPL [225] C5aR deficient and C6 deficient mice and those treated with a C5aR antagonist were similarly protected from aPL-induced endothelial cell activation and thrombosis thus highlighting the importance of the membrane attack complex (MAC) in addition to C5a-C5aR interactions in this pathogenic process [226–228]. Complement activation, through the binding of C5 and MAC to receptors on endothelial cells, can upregulate TF expression and so contribute to thrombus formation [134]. It is likely that complement activation and subsequent generation of potent vasoactive mediators occurs as a necessary intermediary step between endothelial cell and platelet activation by aPL and thrombosis. In fact, a recent cross-sectional retrospective study found that hypocomplementemia was common in patients with primary APS and that it was likely the result of complement activation rather than deficiency. However, no correlation was found between reduced complement levels and thrombotic or obstetric manifestations in these patients [229].

Conclusion

The pathogenic mechanisms by which aPL induce disease expression in APS are manifold and the corollary of this is the exceptional variability in the clinical manifestations observed in these patients. The specific genetic and environmental interactions that occur in individual patients are likely to be particularly important in determining the makeup of the heterogenous aPL milieu found in each, potentially impacting which aPL-induced effects are preferentially activated. Unfortunately, the molecular mechanisms that lead to aPL development and aPL-induced disease expression remain incompletely understood.

The recent elucidation of some of the cell surface interactions of aPL and subsequent intracellular events has led to the identification of novel targets for the treatment and prevention of APS disease manifestations, especially thrombosis [230]. This is quite important as typical anticoagulation therapy with heparin and/or warfarin is sometimes ineffective and has a myriad of side effects, not the least of which is the increased propensity for hemorrhage. The development of therapies that target specific aPL-receptor interactions and distinctive intracellular signaling pathways would ideally result in fewer adverse side effects without sacrificing therapeutic efficacy.

The future success of this ‘immunomodulatory’ approach to the treatment of APS relies on the improved understanding of the molecular events that occur in the disease, which can then inform basic and clinical research for drug development and implementation.